Comparison of 6 cycles of isatuximab with lenalidomide, bortezomib and dexamethasone (I-VRd) versus 3 cycles of I-VRd followed by one cycle of high-dose melphalan in newly diagnosed low-risk multiple myeloma. Protocol for a multicenter, prospective, randomized, phase II clinical trial (ELIAS-Trial) - Leitner, Theo; Shumilov, Evgenii; Schwitlick, Christina; Koch, Raphael; Hamm, Franziska; Högner, Marion; Bassermann, Florian; Weisel, Katja; Einsele, Hermann; Kortüm, Martin; Rasche, Leo; Görner, Martin; et al. (Frontiers in Hematology, 2024)